MarketWatch23m
Amgen Says No Link Between MariTide, Bone Density Loss
Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday after a ...
Benzinga.com13h
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Amgen Inc.‘s AMGN stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...
STAT1d
A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value
On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.
Amgen’s AMG-133 Phase 1 bone data ‘seems non-issue,’ says Jefferies
Jefferies reviewed public data from the Phase 1 trial of AMG-133 showing additional measurements of bone density from obesity patients, which ...
Amgen EPS Surpasses Estimates
Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...
JD Supra7d
Amgen Launches Its Aflibercept Biosimilar In the U.S.
After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from ...
Amgen (AMGN) Q3 2024 Earnings Call Transcript
Amgen (NASDAQ: AMGN) Q3 2024 Earnings Call Oct 30, 2024, 4:30 p.m. ET ...
Employee Benefits2d
Amgen receives menopause-friendly employer accreditation
Biotechnology firm Amgen has been awarded menopause-friendly employer accreditation as part of its aim to ensure all of its ...
Investor's Business Daily on MSN14h
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
Amgen stock tumbled late Tuesday on a report that its high-profile weight-loss shot, MariTide, could be linked to bone ...